UMR S658 INSERM, Hôpital Porte Madeleine, 1 Rue Porte Madeleine, BP 2439, 45032 Orléans, France.
Arthritis Res Ther. 2010;12(3):R112. doi: 10.1186/ar3048. Epub 2010 Jun 9.
Increasing evidence support the regulatory role of leptin in osteoarthritis (OA). As high circulating concentrations of leptin disrupt the physiological function of the adipokine in obese individuals, the current study has been undertaken to determine whether the elevated levels of leptin found in the joint from obese OA patients also induce changes in the chondrocyte response to leptin.
Chondrocytes isolated from OA patients with various body mass index (BMI) were treated with 20, 100 or 500 ng/ml of leptin. The expression of cartilage-specific components (aggrecan, type 2 collagen), as well as regulatory (IGF-1, TGFbeta, MMP-13, TIMP 2) or inflammatory (COX-2, iNOS, IL-1) factors was investigated by real-time PCR to evaluate chondrocyte responsiveness to leptin. Furthermore, the effect of body mass index (BMI) on leptin signalling pathways was analyzed with an enzyme-linked immunosorbent assay for STATs activation.
Leptin at 20 ng/ml was unable to modulate gene expression in chondrocytes, except for MMP-13 in obese OA patients. Higher leptin levels induced the expression of IGF-1, type 2 collagen, TIMP-2 and MMP-13. However, the activity of the adipokine was shown to be critically dependent on both the concentration and the BMI of the patients with a negative association between the activation of regulated genes and BMI for 100 ng/ml of adipokine, but a positive association between chondrocyte responsiveness and BMI for the highest leptin dose. In addition, the gene encoding MMP-13 was identified as a target of leptin for chondrocytes originated from obese patients while mRNA level of TIMP-2 was increased in leptin-treated chondrocytes collected from normal or overweight patients. The adipokine at 500 ng/ml triggered signal transduction through a STAT-dependent pathway while 100 ng/ml of leptin failed to activate STAT 3 but induced STAT 1alpha phosphorylation in chondrocytes obtained from obese patients.
The current study clearly showed that characteristics of OA patients and more especially obesity may affect the responsiveness of cultured chondrocytes to leptin. In addition, the BMI-dependent effect of leptin for the expression of TIMP-2 and MMP-13 may explain why obesity is associated with an increased risk for OA.
越来越多的证据表明瘦素在骨关节炎(OA)中起调节作用。由于循环中高浓度的瘦素会破坏肥胖个体中脂肪细胞因子的生理功能,因此进行了本研究以确定肥胖 OA 患者关节中发现的升高水平的瘦素是否也会引起软骨细胞对瘦素反应的变化。
用 20、100 或 500ng/ml 的瘦素处理来自不同体重指数(BMI)的 OA 患者的分离软骨细胞。通过实时 PCR 检测软骨特异性成分(聚集蛋白聚糖、II 型胶原)以及调节因子(IGF-1、TGFbeta、MMP-13、TIMP2)或炎症因子(COX-2、iNOS、IL-1)的表达,以评估软骨细胞对瘦素的反应。此外,通过酶联免疫吸附试验分析 STAT 激活来分析 BMI 对瘦素信号通路的影响。
20ng/ml 的瘦素不能调节软骨细胞的基因表达,除了肥胖 OA 患者的 MMP-13。较高的瘦素水平诱导 IGF-1、II 型胶原、TIMP-2 和 MMP-13 的表达。然而,该脂肪细胞因子的活性被证明严重依赖于患者的浓度和 BMI,对于 100ng/ml 的脂肪细胞因子,调节基因的激活与 BMI 呈负相关,但对于最高剂量的瘦素,软骨细胞的反应性与 BMI 呈正相关。此外,编码 MMP-13 的基因被鉴定为肥胖患者来源的软骨细胞的瘦素靶标,而 TIMP-2 的 mRNA 水平在瘦素处理的软骨细胞中增加,这些软骨细胞来自正常或超重患者。500ng/ml 的脂肪细胞因子通过 STAT 依赖性途径触发信号转导,而 100ng/ml 的瘦素未能激活 STAT3,但在肥胖患者来源的软骨细胞中诱导 STAT1alpha 磷酸化。
本研究清楚地表明,OA 患者的特征,特别是肥胖,可能会影响培养的软骨细胞对瘦素的反应性。此外,瘦素对 TIMP-2 和 MMP-13 表达的 BMI 依赖性影响可能解释为什么肥胖与 OA 风险增加有关。